Skip to content

Study · Case report or series · n = 1 · 2007

6 results

Adult hypophosphatasia treated with teriparatide.

Whyte MP, Mumm S, Deal C

The Journal of clinical endocrinology and metabolism9 Jan 2007Cited by 106 (Europe PMC)

PMID17213282 (opens in a new tab)DOI10.1210/jc.2006-1902 (opens in a new tab)PepBankPUB-17213282
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, fracture pain improved after six weeks of teriparatide and resolved after 4 months.

    In plain wordsFracture pain improved and then resolved during teriparatide treatment in one woman with hypophosphatasia.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture pain
    Study

    n = 1

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Six weeks later, all fracture pain improved, and it resolved after 4 months.
    2 context sentences
    Summary · context
    A middle-aged woman sustained a slowly healing MTSF and then two enlarging MTSFs and a spontaneous proximal femur fracture.
    Summary · context
    Teriparatide (TPTD) (recombinant human PTH 1-34), 20 microg, was injected sc daily in an attempt to enhance osteoblast synthesis of TNSALP.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, enlarging metatarsal stress fractures showed radiographic repair after 2-4 months of teriparatide.

    In plain wordsFoot stress fractures showed repair during teriparatide treatment in one woman with hypophosphatasia.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMetatarsal stress fracture repair
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Radiographs of the enlarging MTSFs showed repair after 2-4 months.
    2 context sentences
    Summary · context
    A middle-aged woman sustained a slowly healing MTSF and then two enlarging MTSFs and a spontaneous proximal femur fracture.
    Summary · context
    Teriparatide (TPTD) (recombinant human PTH 1-34), 20 microg, was injected sc daily in an attempt to enhance osteoblast synthesis of TNSALP.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, the femur fracture partially mended after 2 months of teriparatide and subsequently healed.

    In plain wordsA thigh bone fracture partly repaired and then healed during teriparatide treatment in one woman.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemur fracture healing
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The femur fracture partially mended after 2 months and then healed.
    2 context sentences
    Summary · context
    A middle-aged woman sustained a slowly healing MTSF and then two enlarging MTSFs and a spontaneous proximal femur fracture.
    Summary · context
    Teriparatide (TPTD) (recombinant human PTH 1-34), 20 microg, was injected sc daily in an attempt to enhance osteoblast synthesis of TNSALP.
  4. 04HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, low alkaline phosphatase activity corrected during teriparatide treatment.

    In plain wordsLow alkaline phosphatase activity corrected during teriparatide treatment in one woman.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseHypophosphatasemia
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Additionally, hypophosphatasemia and hyperphosphatemia corrected, and biochemical markers of bone remodeling increased as long as TPTD (given for 18 months) was continued.
    2 context sentences
    Summary · context
    A middle-aged woman sustained a slowly healing MTSF and then two enlarging MTSFs and a spontaneous proximal femur fracture.
    Summary · context
    Teriparatide (TPTD) (recombinant human PTH 1-34), 20 microg, was injected sc daily in an attempt to enhance osteoblast synthesis of TNSALP.
  5. 05HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, hyperphosphatemia corrected during teriparatide treatment.

    In plain wordsHigh blood phosphate corrected during teriparatide treatment in one woman.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseHyperphosphatemia
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Additionally, hypophosphatasemia and hyperphosphatemia corrected, and biochemical markers of bone remodeling increased as long as TPTD (given for 18 months) was continued.
    2 context sentences
    Summary · context
    A middle-aged woman sustained a slowly healing MTSF and then two enlarging MTSFs and a spontaneous proximal femur fracture.
    Summary · context
    Teriparatide (TPTD) (recombinant human PTH 1-34), 20 microg, was injected sc daily in an attempt to enhance osteoblast synthesis of TNSALP.
  6. 06HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, bone remodeling markers increased while teriparatide treatment continued.

    In plain wordsBone remodeling markers increased during teriparatide treatment in one woman.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone remodeling markers
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Additionally, hypophosphatasemia and hyperphosphatemia corrected, and biochemical markers of bone remodeling increased as long as TPTD (given for 18 months) was continued.
    2 context sentences
    Summary · context
    A middle-aged woman sustained a slowly healing MTSF and then two enlarging MTSFs and a spontaneous proximal femur fracture.
    Summary · context
    Teriparatide (TPTD) (recombinant human PTH 1-34), 20 microg, was injected sc daily in an attempt to enhance osteoblast synthesis of TNSALP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.